

METHODS IN MOLECULAR BIOLOGY™

Series Editor
John M. Walker
School of Life Sciences
University of Hertfordshire
Hatfield, Hertfordshire, AL10 9AB, UK

For further volumes:
<http://www.springer.com/series/7651>

Tissue-Protective Cytokines

Methods and Protocols

Edited by

Pietro Ghezzi

Brighton and Sussex Medical School, Falmer, UK

Anthony Cerami

Leiden University Medical Center, Leiden, The Netherlands

 Humana Press

Editors

Pietro Ghezzi
Brighton and Sussex Medical School
Falmer, UK

Anthony Cerami
Leiden University Medical Center
Leiden, The Netherlands

ISSN 1064-3745 ISSN 1940-6029 (electronic)
ISBN 978-1-62703-307-7 ISBN 978-1-62703-308-4 (eBook)
DOI 10.1007/978-1-62703-308-4
Springer New York Heidelberg Dordrecht London

Library of Congress Control Number: 2013932704

© Springer Science+Business Media, LLC 2013

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher's location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Printed on acid-free paper

Humana Press is a brand of Springer
Springer is part of Springer Science+Business Media (www.springer.com)

Preface

In 2004, Pietro Ghezzi asked me to write a short introductory chapter for a book on TNF he was putting together for this very same series. The focus of what I wrote then was on TNF as an inflammatory agent. In fact, our finding, in the 1980s, that cachexia associated with inflammatory and infectious diseases was due to TNF opened the way to the development of anti-TNF drugs that are now standard treatment for chronic inflammatory disease.

Now, I am asked again to write about the continuation of this saga. In 1998, with Mike Brines and Carla Hand, I started investigating why patients who receive EPO feel well soon after the first treatment. That led to the discovery, published in 2000, that systemically administered EPO is neuroprotective in animal models of ischemic and traumatic brain injury. That paper opened the field of the neuroprotective action of EPO. The protective action of EPO was soon demonstrated in other tissues, hence the use of the term “tissue-protective cytokine” (1). As in the case of TNF, we had to fight the commonplace that EPO has only erythropoietic actions, that its receptor is present only in erythroid progenitor cells, and that EPO is produced only by the kidney (2).

As in the case of TNF, originally identified for its antitumor activities, we had to work against the common belief that EPO is solely an erythropoietic cytokine acting solely on erythroid progenitors. Several investigators also documented the expression of EPO in the central nervous system and other tissues, against the common belief that only the kidney and the foetal liver produce EPO.

From the perspective of pharmacological use, the erythropoietic action of EPO, by increasing the haematocrit and activating platelets, has some undesired side effects as a tissue-protectant, and this led to the development of novel non-erythropoietic EPO-derived tissue-protective molecules some of which are described here.

I believe that tissue-protection will be a new field of interest of cytokine biology, both in discovering novel actions of known cytokines and in developing new drugs. In this context, this book is a valuable collection of methodological papers that describe in detail the key models that have been used to characterize the tissue-protective actions of EPO and derivatives and will, hopefully, be of use in the discovery of new tissue-protective molecules.

Leiden, The Netherlands

Anthony Cerami

References

1. Cerami A (2011) The value of failure: the discovery of TNF and its natural inhibitor erythropoietin. *J Intern Med* 269(1):8–15
2. Ghezzi P, Bernaudin M, Bianchi R, Blomgren K, Brines M, Campana W, Cavaletti G, Cerami A, Chopp M, Coleman T, Digicaylioglu M, Ehrenreich H, Erbayraktar S, Erbayraktar Z, Gassmann M, Genc S, Gokmen N, Grasso G, Juul S, Lipton SA, Hand CC, Latini R, Lauria G, Leist M, Newton SS, Petit E, Probert L, Sfacteria A, Siren AL, Talan M, Thiemermann C, Westenbrink D, Yaqoob M, Zhu C (2010) Erythropoietin: not just about erythropoiesis. *Lancet* 375(9732):2142

Contents

<i>Preface</i>	<i>v</i>
<i>Contributors</i>	<i>ix</i>
1 Erythropoietin and Engineered Innate Repair Activators	1
<i>Michael Brines and Anthony Cerami</i>	
2 Epo and Non-hematopoietic Cells: What Do We Know?	13
<i>Omolara O. Ogunshola and Anna Yu. Bogdanova</i>	
3 Tissue-Protective Cytokines: Structure and Evolution	43
<i>Pietro Ghezzi and Darrell Conklin</i>	
4 The Regenerative Activity of Interleukin-6	59
<i>Eithan Galun and Stefan Rose-John</i>	
5 Brain Ischemic Injury in Rodents: The Protective Effect of EPO	79
<i>Annelise Letourneur, Edwige Petit, Simon Roussel, Omar Touzani, and Myriam Bernaudin</i>	
6 Experimental Traumatic Spinal Cord Injury	103
<i>Zübeyde Erbayraktar, Necati Gökmen, Osman Yılmaz, and Serhat Erbayraktar</i>	
7 Erythropoietin as a Neuroprotectant for Neonatal Brain Injury: Animal Models	113
<i>Christopher M. Traudt and Sandra E. Juul</i>	
8 Evaluating Effects of EPO in Rodent Behavioral Assays Related to Depression	127
<i>Catharine H. Duman and Samuel S. Newton</i>	
9 Erythropoietin and Cytoprotective Cytokines in Experimental Traumatic Brain Injury	141
<i>Samson Kumar Gaddam, Jovany Cruz, and Claudia Robertson</i>	
10 Therapeutic Efficacy of Erythropoietin in Experimental Autoimmune Encephalomyelitis in Mice, a Model of Multiple Sclerosis	163
<i>Iliaria Cervellini, Pietro Ghezzi, and Manuela Mengozzi</i>	
11 Deciphering the Intracellular Signaling of Erythropoietin in Neuronal Cells	175
<i>Murat Digicaylioglu</i>	
12 Assessment of Allodynia Relief by Tissue-Protective Molecules in a Rat Model of Nerve Injury-Induced Neuropathic Pain	187
<i>Maarten Swartjes, Marieke Niesters, and Albert Dahan</i>	
13 Intra-epidermal Nerve Fibers Density and Nociception in EPO-Treated Type 1 Diabetic Rats with Peripheral Neuropathy	197
<i>Bianchi Roberto, Lombardi Raffaella, Porretta-Serapiglia Carla, and Lauria Giuseppe</i>	

14	ARA290 in a Rat Model of Inflammatory Pain	213
	<i>Andrew Dilley</i>	
15	In Vivo Angiogenic Activity of Erythropoietin.	227
	<i>Domenico Ribatti</i>	
16	Photoreceptor Degeneration in Mice: Adeno-Associated Viral Vector-Mediated Delivery of Erythropoietin	237
	<i>Pasqualina Colella and Alberto Auricchio</i>	
17	Myocardial Infarction: Cardioprotection by Erythropoietin	265
	<i>Mark I. Talan and Roberto Latini</i>	
18	Using Plethysmography to Determine Erythropoietin’s Impact on Neural Control of Ventilation.	303
	<i>Tommy Seaborn, Max Gassmann, and Jorge Soliz</i>	
19	Cerebral Malaria: Protection by Erythropoietin.	315
	<i>Anne-Lise Bienvenu and Stephane Picot</i>	
	<i>Index</i>	325

Contributors

- ALBERTO AURICCHIO • *Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy; Medical Genetics, Department of Medical Translational Science, Federico II University, Naples, Italy*
- MYRIAM BERNAUDIN • *CERVOxy team “Hypoxia, cerebrovascular and tumoral pathophysiology”, UMR 6301-ISTCT, CNRS, CEA, Université de Caen Basse-Normandie, CYCERON, Caen, France*
- ANNE-LISE BIENVENU • *Malaria Research Unit, SMITH ICBMS UMR CNRS, UCBL, INSA Lyon, Lyon, France*
- ANNA YU. BOGDANOVA • *Institute of Veterinary Physiology, Vetsuisse Faculty and Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Zurich, Switzerland*
- MICHAEL BRINES • *Araim Pharmaceuticals, Inc., Ossining, NY, USA*
- PORRETTA-SERAPIGLIA CARLA • *Neuromuscular Diseases Unit, IRCCS Foundation, “Carlo Besta” Neurological Institute, Milan, Italy*
- ANTHONY CERAMI • *Araim Pharmaceuticals, Ossining, NY, USA; Leiden University Medical Center, Leiden, The Netherlands*
- ILARIA CERVELLINI • *Brighton & Sussex Medical School, Falmer, UK*
- PASQUALINA COLELLA • *Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy*
- DARRELL CONKLIN • *Department of Computer Science and Artificial Intelligence, University of the Basque Country UPV/EHU, San Sebastián, Spain; IKERBASQUE, Basque Foundation for Science, Bilbao, Spain*
- JOVANY CRUZ • *Baylor College of Medicine, Houston, TX, USA*
- ALBERT DAHAN • *Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands*
- MURAT DIGICAYLIOGLU • *Departments of Neurosurgery and Physiology, University of Texas Health Science Center, San Antonio, TX, USA*
- ANDREW DILLEY • *Brighton and Sussex Medical School, Falmer, UK*
- CATHARINE H. DUMAN • *Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA*
- SERHAT ERBAYRAKTAR • *Department of Neurosurgery, School of Medicine, Dokuz Eylul University, İnciralti, İzmir, Turkey*
- ZÜBEYDE ERBAYRAKTAR • *Department of Medical Biochemistry, School of Medicine, Dokuz Eylul University, İnciralti, İzmir, Turkey*
- SAMSON KUMAR GADDAM • *Baylor College of Medicine, Houston, TX, USA*
- EITHAN GALUN • *Goldyne Savad Inst. of Gene Therapy, Hadassah Hebrew University Hospital, Jerusalem, Israel*
- MAX GASSMANN • *Institute of Veterinary Physiology, Vetsuisse Faculty and Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Zurich, Switzerland*

- PIETRO GHEZZI • *Brighton & Sussex Medical School, Falmer, UK*
- LAURIA GIUSEPPE • *Neuromuscular Diseases Unit, IRCCS Foundation, “Carlo Besta” Neurological Institute, Milan, Italy*
- NECATI GOKMEN • *Department of Anesthesia and Reanimation, School of Medicine, Dokuz Eylul University, Inciralti, Izmir, Turkey*
- SANDRA E. JUUL • *Division of Neonatology, Department of Pediatrics, University of Washington, Seattle, WA, USA*
- ROBERTO LATINI • *Department of Cardiovascular Research, Istituto Mario Negri, Milan, Italy*
- ANNELISE LETOURNEUR • *CERVOxy team “Hypoxia, cerebrovascular and tumoral pathophysiology”, UMR 6301-ISTCT, CNRS, CEA, Université de Caen Basse-Normandie, CYCERON, Caen, France*
- MANUELA MENGOSZI • *Brighton & Sussex Medical School, Falmer, UK*
- SAMUEL S. NEWTON • *Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA*
- MARIEKE NIESTERS • *Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands*
- OMOLARA O. OGUNSHOLA • *Institute of Veterinary Physiology, Vetsuisse Faculty and Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Zurich, Switzerland*
- EDWIGE PETIT • *CERVOxy team “Hypoxia, cerebrovascular and tumoral pathophysiology”, UMR 6301-ISTCT, CNRS, CEA, Université de Caen Basse-Normandie, CYCERON, Caen, France*
- STEPHANE PICOT • *Malaria Research Unit, SMITH ICBMS UMR CNRS, UCBL, INSA Lyon, Lyon, France*
- LOMBARDI RAFFAELLA • *Neuromuscular Diseases Unit, IRCCS Foundation, “Carlo Besta” Neurological Institute, Milan, Italy*
- DOMENICO RIBATTI • *Department of Basic Medical Sciences, Neurosciences, and Sensory Organs, University of Bari Medical School, Bari, Italy*
- BIANCHI ROBERTO • *Neuromuscular Diseases Unit, IRCCS Foundation, “Carlo Besta” Neurological Institute, Milan, Italy*
- CLAUDIA ROBERTSON • *Department of Neurosurgery, Baylor College of Medicine, Houston, TX, USA*
- STEFAN ROSE-JOHN • *Institut für Biochemie, Christian-Albrechts-Universität zu Kiel, Kiel, Germany*
- SIMON ROUSSEL • *CERVOxy team “Hypoxia, cerebrovascular and tumoral pathophysiology”, UMR 6301-ISTCT, CNRS, CEA, Université de Caen Basse-Normandie, CYCERON, Caen, France*
- TOMMY SEABORN • *Faculty of Medicine, Department of Pediatrics, Centre de Recherche de l’Hôpital St-François d’Assise (CR-SFA), Centre Hospitalier Universitaire de Québec (CHUQ), Laval University, Québec, QC, Canada*
- JORGE SOLIZ • *Faculty of Medicine, Department of Pediatrics, Centre de Recherche de l’Hôpital St-François d’Assise (CR-SFA), Centre Hospitalier Universitaire de Québec (CHUQ), Laval University, Québec, QC, Canada*
- MAARTEN SWARTJES • *Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands*

MARK I. TALAN • *Laboratory of Cardiovascular Sciences, National Institute on Aging, NIH, Baltimore, MD, USA*

OMAR TOUZANI • *CERVOxy team “Hypoxia, cerebrovascular and tumoral pathophysiologies”, UMR 6301-ISTCT, CNRS, CEA, Université de Caen Basse-Normandie, CYCERON, Caen, France*

CHRISTOPHER M. TRAUDT • *Division of Neonatology, Department of Pediatrics, University of Washington, Seattle, WA, USA*

OSMAN YILMAZ • *Animal Research Center, School of Medicine, Dokuz Eylul University, İnciralti, İzmir, Turkey*